LG
DXCM icon

LaFleur & Godfrey’s DexCom DXCM Stock Holding History

LaFleur & Godfrey’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,374
Closed -$262K – 147
2024
Q4 		$262K Buy
3,374
+35
+1% +$2.59K 0.04% 128
2024
Q3 		$224K Sell
3,339
-1,905
-36% -$156K 0.03% 137
2024
Q2 		$595K Buy
5,244
+261
+5% +$33K 0.09% 92
2024
Q1 		$691K Buy
4,983
+797
+19% +$100K 0.1% 87
2023
Q4 		$519K Sell
4,186
-380
-8% -$38.8K 0.08% 92
2023
Q3 		$426K Buy
4,566
+2,966
+185% +$334K 0.07% 94
2023
Q2 		$206K Buy
+1,600
New +$194K 0.03% 123
2021
Q4 		– Sell
-1,504
Closed -$206K – 128
2021
Q3 		$206K Buy
+1,504
New +$190K 0.03% 125

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

LaFleur & Godfrey's DXCM Position: Q1 2025 in Review

LaFleur & Godfrey sold out of DexCom (DXCM) in Q1 2025, closing a stake of 3,374 shares — an estimated $262K sold.

LaFleur & Godfrey first reported a position in DXCM in Q3 2021 and held it in 8 quarters. The position peaked at $691K in Q1 2024. 932 funds tracked by Wall St. Rank hold DXCM as of Q1 2025.

  • LaFleur & Godfrey reported no remaining DexCom position as of Q1 2025 after selling out during the quarter.
  • LaFleur & Godfrey sold 3,374 DexCom shares in Q1 2025, an estimated $262K.
  • LaFleur & Godfrey first reported a position in DexCom in Q3 2021 and held it in 8 quarters.
  • LaFleur & Godfrey's DexCom position peaked at $691K in Q1 2024.
  • 932 funds tracked by Wall St. Rank held DexCom as of Q1 2025.

Based on LaFleur & Godfrey's 13F filing for Q1 2025, filed 23 Apr 2025.